Celiac Disease: Role of the Epithelial Barrier

Cellular and Molecular Gastroenterology and Hepatology

Volumn 3, Issue 2, 2017, Pages 150-162

  Schumann, Michael ^a,b,c   Siegmund, Britta ^a   Schulzke, Jörg D ^a   Fromm, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BERLIN INSTITUTE OF HEALTH   (Germany)

^c Berlin Brandenburg School for Regenerative Therapies   (Germany)

Author keywords

Celiac Sprue; Epithelial Polarity; Gluten Sensitive Enteropathy; Partitioning Defective Proteins; Tight Junction; Gliadin 33mer

Indexed keywords

GLIADIN; GLUTEN; TIGHT JUNCTION PROTEIN;

ADHERENS JUNCTION; ALTERNATIVE MEDICINE; APOPTOSIS; CELIAC DISEASE; CELL POLARITY; GENETICS; GLUTEN FREE DIET; HUMAN; INTESTINAL STEM CELL; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; LIVER DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW;

EID: 85014088481     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2016.12.006     Document Type: Review

References (122)

1. 1 Felber, J., Aust, D., Baas, S., et al. Ergebnisse einer S2k-Konsensuskonferenz der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselerkrankungen (DGVS) gemeinsam mit der Deutschen Zöliakie-Gesellschaft (DZG e. V.) zur Zöliakie, Weizenallergie und Weizensensitivität. Z Gastroenterol 52 (2014), 711–743.
2. 2 Ludvigsson, J.F., Leffler, D.A., Bai, J.C., et al. The Oslo definitions for coeliac disease and related terms. Gut 62 (2013), 43–52.
3. 3 Fasano, A., Berti, I., Gerarduzzi, T., et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 163 (2003), 286–292.
4. 4 Goddard, C.J., Gillett, H.R., Complications of coeliac disease: are all patients at risk?. Postgrad Med J 82 (2006), 705–712.
5. 5 Lewis, N.R., Holmes, G.K., Risk of morbidity in contemporary celiac disease. Expert Rev Gastroenterol Hepatol 4 (2010), 767–780.
6. 6 Mustalahti, K., Catassi, C., Reunanen, A., et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med 42 (2010), 587–595.
7. 7 van Elburg, R.M., Uil, J.J., Mulder, C.J., et al. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 34 (1993), 354–357.
8. 8 Smecuol, E., Bai, J.C., Vazquez, H., et al. Gastrointestinal permeability in celiac disease. Gastroenterology 112 (1997), 1129–1136.
9. 9 Vogelsang, H., Schwarzenhofer, M., Steiner, B., et al. In vivo and in vitro permeability in coeliac disease. Aliment Pharmacol Ther 15 (2001), 1417–1425.
10. 10 Singh, P., Arora, S., Lal, S., et al. Risk of celiac disease in the first- and second-degree relatives of patients with celiac disease: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 1539–1548.
11. 11 Book, L., Zone, J.J., Neuhausen, S.L., Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol 98 (2003), 377–381.
12. 12 Nistico, L., Fagnani, C., Coto, I., et al. Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut 55 (2006), 803–808.
13. 13 Karell, K., Louka, A.S., Moodie, S.J., et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 64 (2003), 469–477.
14. 14 Sollid, L.M., Markussen, G., Ek, J., et al. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 169 (1989), 345–350.
15. 15 van Belzen, M.J., Koeleman, B.P., Crusius, J.B., et al. Defining the contribution of the HLA region to cis DQ2-positive coeliac disease patients. Genes Immun 5 (2004), 215–220.
16. 16 Kumar, V., Wijmenga, C., Withoff, S., From genome-wide association studies to disease mechanisms: celiac disease as a model for autoimmune diseases. Semin Immunopathol 34 (2012), 567–580.
17. 17 van Heel, D.A., Franke, L., Hunt, K.A., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 39 (2007), 827–829.
18. 18 Dubois, P.C., Trynka, G., Franke, L., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 42 (2010), 295–302.
19. 19 Trynka, G., Hunt, K.A., Bockett, N.A., et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 43 (2011), 1193–1201.
20. 20 Kumar, V., Gutierrez-Achury, J., Kanduri, K., et al. Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels. Hum Mol Genet 24 (2015), 397–409.
21. 21 Zhernakova, A., Stahl, E.A., Trynka, G., et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet, 7, 2011, e1002004.
22. 22 Wijmenga, C., Gutierrez-Achury, J., Celiac disease genetics: past, present and future challenges. J Pediatr Gastroenterol Nutr 59:Suppl 1 (2014), S4–S7.
23. 23 Rampertab, S.D., Pooran, N., Brar, P., et al. Trends in the presentation of celiac disease. Am J Med, 119, 2006, 355 e9–14.
24. 24 Ivarsson, A., Persson, L.A., Nystrom, L., et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr 89 (2000), 165–171.
25. 25 Ivarsson, A., The Swedish epidemic of coeliac disease explored using an epidemiological approach–some lessons to be learnt. Best Pract Res Clin Gastroenterol 19 (2005), 425–440.
26. 26 Vriezinga, S.L., Auricchio, R., Bravi, E., et al. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med 371 (2014), 1304–1315.
27. 27 Lionetti, E., Castellaneta, S., Francavilla, R., et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med 371 (2014), 1295–1303.
28. 28 Andren Aronsson, C., Lee, H.S., Koletzko, S., et al. Effects of gluten intake on risk of celiac disease: a case-control study on a Swedish birth cohort. Clin Gastroenterol Hepatol 14 (2016), 403–409 e3.
29. 29 Kagnoff, M.F., Paterson, Y.J., Kumar, P.J., et al. Evidence for the role of a human intestinal adenovirus in the pathogenesis of coeliac disease. Gut 28 (1987), 995–1001.
30. 30 Marild, K., Kahrs, C.R., Tapia, G., et al. Infections and risk of celiac disease in childhood: a prospective nationwide cohort study. Am J Gastroenterol 110 (2015), 1475–1484.
31. 31 Riddle, M.S., Murray, J.A., Cash, B.D., et al. Pathogen-specific risk of celiac disease following bacterial causes of foodborne illness: a retrospective cohort study. Dig Dis Sci 58 (2013), 3242–3245.
32. 32 Stene, L.C., Honeyman, M.C., Hoffenberg, E.J., et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 101 (2006), 2333–2340.
33. 33 Matysiak-Budnik, T., Moura, I.C., Arcos-Fajardo, M., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 205 (2008), 143–154.
34. 34 Schumann, M., Kamel, S., Pahlitzsch, M.L., et al. Defective tight junctions in refractory celiac disease. Ann N Y Acad Sci 1258 (2012), 43–51.
35. 35 Schumann, M., Richter, J.F., Wedell, I., et al. Mechanisms of epithelial translocation of the {alpha}2-gliadin-33mer in celiac sprue. Gut 57 (2008), 747–754.
36. 36 Sato, T., Vries, R.G., Snippert, H.J., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459 (2009), 262–265.
37. 37 Clevers, H.C., Bevins, C.L., Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol 75 (2013), 289–311.
38. 38 Sato, T., van Es, J.H., Snippert, H.J., et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469 (2011), 415–418.
39. 39 Rubio, C.A., Lysozyme-rich mucus metaplasia in duodenal crypts supersedes Paneth cells in celiac disease. Virchows Arch 459 (2011), 339–346.
40. 40 Scott, H., Brandtzaeg, P., Enumeration of Paneth cells in coeliac disease: comparison of conventional light microscopy and immunofluorescence staining for lysozyme. Gut 22 (1981), 812–816.
41. 41 Di Sabatino, A., Miceli, E., Dhaliwal, W., et al. Distribution, proliferation, and function of Paneth cells in uncomplicated and complicated adult celiac disease. Am J Clin Pathol 130 (2008), 34–42.
42. 42 Juuti-Uusitalo, K., Maki, M., Kainulainen, H., et al. Gluten affects epithelial differentiation-associated genes in small intestinal mucosa of coeliac patients. Clin Exp Immunol 150 (2007), 294–305.
43. 43 Liang, R., Hinds, R., Abud, H.E., et al. Hedgehog signalling is downregulated in celiac disease. Can J Gastroenterol 27 (2013), e5–e7.
44. 44 Ciclitira, P.J., Stewart, J., Evan, G., et al. Expression of c-myc oncogene in coeliac disease. J Clin Pathol 40 (1987), 307–311.
45. 45 Oittinen, M., Popp, A., Kurppa, K., et al. Polycomb repressive complex 2 enacts Wnt signaling in intestinal homeostasis and contributes to the instigation of stemness in diseases entailing epithelial hyperplasia or neoplasia. Stem Cells 35 (2017), 445–457.
46. 46 Haramis, A.P., Begthel, H., van den Born, M., et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 303 (2004), 1684–1686.
47. 47 Muncan, V., Sansom, O.J., Tertoolen, L., et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol Cell Biol 26 (2006), 8418–8426.
48. 48 Wong, V.W., Stange, D.E., Page, M.E., et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 14 (2012), 401–408.
49. 49 Batlle, E., Henderson, J.T., Beghtel, H., et al. Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111 (2002), 251–263.
50. 50 Ciccocioppo, R., Di Sabatino, A., Parroni, R., et al. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 115 (2001), 494–503.
51. 51 Maiuri, L., Ciacci, C., Raia, V., et al. FAS engagement drives apoptosis of enterocytes of coeliac patients. Gut 48 (2001), 418–424.
52. 52 Schumann, M., Günzel, D., Buergel, N., et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut 61 (2012), 220–228.
53. 53 Shalimar, D.M., Das, P., Sreenivas, V., et al. Mechanism of villous atrophy in celiac disease: role of apoptosis and epithelial regeneration. Arch Pathol Lab Med 137 (2013), 1262–1269.
54. 54 Di Sabatino, A., Ciccocioppo, R., Cupelli, F., et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55 (2006), 469–477.
55. 55 Maiuri, L., Ciacci, C., Auricchio, S., et al. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119 (2000), 996–1006.
56. 56 Groh, V., Bahram, S., Bauer, S., et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 93 (1996), 12445–12450.
57. 57 Hue, S., Mention, J.J., Monteiro, R.C., et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21 (2004), 367–377.
58. 58 Mazzarella, G., Stefanile, R., Camarca, A., et al. Gliadin activates HLA class I-restricted CD8+ T cells in celiac disease intestinal mucosa and induces the enterocyte apoptosis. Gastroenterology 134 (2008), 1017–1027.
59. 59 Dema, B., Fernandez-Arquero, M., Maluenda, C., et al. Lack of association of NKX2-3, IRGM, and ATG16L1 inflammatory bowel disease susceptibility variants with celiac disease. Hum Immunol 70 (2009), 946–949.
60. 60 Weersma, R.K., Zhernakova, A., Nolte, I.M., et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol 103 (2008), 621–627.
61. 61 Ricano-Ponce, I., Zhernakova, D.V., Deelen, P., et al. Refined mapping of autoimmune disease associated genetic variants with gene expression suggests an important role for non-coding RNAs. J Autoimmun 68 (2016), 62–74.
62. 62 Quiros, M., Nusrat, A., RhoGTPases, actomyosin signaling and regulation of the epithelial apical junctional complex. Semin Cell Dev Biol 36C (2014), 194–203.
63. 63 Turner, J.R., Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9 (2009), 799–809.
64. 64 Amasheh, S., Meiri, N., Gitter, A.H., et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 115 (2002), 4969–4976.
65. 65 Günzel, D., Stuiver, M., Kausalya, P.J., et al. Claudin-10 exists in six alternatively spliced isoforms that exhibit distinct localization and function. J Cell Sci 122 (2009), 1507–1517.
66. 66 Krug, S.M., Günzel, D., Conrad, M.P., et al. Claudin-17 forms tight junction channels with distinct anion selectivity. Cell Mol Life Sci 69 (2012), 2765–2778.
67. 67 Rosenthal, R., Milatz, S., Krug, S.M., et al. Claudin-2, a component of the tight junction, forms a paracellular water channel. J Cell Sci 123 (2010), 1913–1921.
68. 68 Krug, S.M., Schulzke, J.D., Fromm, M., Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol 36 (2014), 166–176.
69. 69 Fromm, M., Krug, S.M., Zeissig, S., et al. High-resolution analysis of barrier function. Ann N Y Acad Sci 1165 (2009), 74–81.
70. 70 Schulzke, J.D., Bentzel, C.J., Schulzke, I., et al. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 43 (1998), 435–441.
71. 71 Günzel, D., Fromm, M., Claudins and other tight junction proteins. Compr Physiol 2 (2012), 1819–1852.
72. 72 Szakal, D.N., Gyorffy, H., Arato, A., et al. Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease. Virchows Arch 456 (2010), 245–250.
73. 73 Buschmann, M.M., Shen, L., Rajapakse, H., et al. Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux. Mol Biol Cell 24 (2013), 3056–3068.
74. 74 Chandhoke, S.K., Mooseker, M.S., A role for myosin IXb, a motor-RhoGAP chimera, in epithelial wound healing and tight junction regulation. Mol Biol Cell 23 (2012), 2468–2480.
75. 75 Ciccocioppo, R., Finamore, A., Ara, C., et al. Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am J Clin Pathol 125 (2006), 502–511.
76. 76 Wapenaar, M.C., Monsuur, A.J., van Bodegraven, A.A., et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 57 (2008), 463–467.
77. 77 Kemphues, K.J., Priess, J.R., Morton, D.G., et al. Identification of genes required for cytoplasmic localization in early C. elegans embryos. Cell 52 (1988), 311–320.
78. 78 Goldstein, B., Macara, I.G., The PAR proteins: fundamental players in animal cell polarization. Dev Cell 13 (2007), 609–622.
79. 79 McCaffrey, L.M., Macara, I.G., Signaling pathways in cell polarity. Cold Spring Harb Perspect Biol 4 (2012), 1–15.
80. 80 Goehring, N.W., Hoege, C., Grill, S.W., et al. PAR proteins diffuse freely across the anterior-posterior boundary in polarized C. elegans embryos. J Cell Biol 193 (2011), 583–594.
81. 81 Suzuki, A., Yamanaka, T., Hirose, T., et al. Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol 152 (2001), 1183–1196.
82. 82 Ebnet, K., Schulz, C.U., Meyer Zu Brickwedde, M.K., et al. Junctional adhesion molecule interacts with the PDZ domain-containing proteins AF-6 and ZO-1. J Biol Chem 275 (2000), 27979–27988.
83. 83 Hurd, T.W., Fan, S., Liu, C.J., et al. Phosphorylation-dependent binding of 14-3-3 to the polarity protein Par3 regulates cell polarity in mammalian epithelia. Curr Biol 13 (2003), 2082–2090.
84. 84 Benton, R., St Johnston, D., Drosophila PAR-1 and 14-3-3 inhibit Bazooka/PAR-3 to establish complementary cortical domains in polarized cells. Cell 115 (2003), 691–704.
85. 85 Traweger, A., Wiggin, G., Taylor, L., et al. Protein phosphatase 1 regulates the phosphorylation state of the polarity scaffold Par-3. Proc Natl Acad Sci U S A 105 (2008), 10402–10407.
86. 86 Spicer, J., Rayter, S., Young, N., et al. Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Oncogene 22 (2003), 4752–4756.
87. 87 Baas, A.F., Kuipers, J., van der Wel, N.N., et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 116 (2004), 457–466.
88. 88 Xu, X., Jin, D., Durgan, J., et al. LKB1 controls human bronchial epithelial morphogenesis through p114RhoGEF-dependent RhoA activation. Mol Cell Biol 33 (2013), 2671–2682.
89. 89 Hearle, N., Schumacher, V., Menko, F.H., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12 (2006), 3209–3215.
90. 90 Wang, W., Uzzau, S., Goldblum, S.E., et al. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 113 (2000), 4435–4440.
91. 91 Tripathi, A., Lammers, K.M., Goldblum, S., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 106 (2009), 16799–16804.
92. 92 Khaleghi, S., Ju, J.M., Lamba, A., et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol 9 (2016), 37–49.
93. 93 Thomas, K.E., Sapone, A., Fasano, A., et al. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 176 (2006), 2512–2521.
94. 94 Lammers, K.M., Lu, R., Brownley, J., et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 135 (2008), 194–204 e3.
95. 95 Fasano, A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 91 (2011), 151–175.
96. 96 Vanuytsel, T., Vermeire, S., Cleynen, I., The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease. Tissue Barriers, 1, 2013, e27321.
97. 97 Nilsen, E.M., Lundin, K.E., Krajci, P., et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 37 (1995), 766–776.
98. 98 Ontiveros, N., Tye-Din, J.A., Hardy, M.Y., et al. Ex-vivo whole blood secretion of interferon (IFN)-gamma and IFN-gamma-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-gamma enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2.5(+) -associated coeliac disease. Clin Exp Immunol 175 (2014), 305–315.
99. 99 Epple, H.J., Schneider, T., Troeger, H., et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 58 (2009), 220–227.
100. 100 Heller, F., Florian, P., Bojarski, C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2005), 550–564.
101. 101 Nusrat, A., von Eichel-Streiber, C., Turner, J.R., et al. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 69 (2001), 1329–1336.
102. 102 Schmitz, H., Barmeyer, C., Fromm, M., et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116 (1999), 301–309.
103. 103 Troeger, H., Epple, H.J., Schneider, T., et al. Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum. Gut 56 (2007), 328–335.
104. 104 Zeissig, S., Bojarski, C., Buergel, N., et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 53 (2004), 1295–1302.
105. 105 Zeissig, S., Bürgel, N., Günzel, D., et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56 (2007), 61–72.
106. 106 Schulzke, J.D., Schulzke, I., Fromm, M., et al. Epithelial barrier and ion transport in coeliac sprue: electrical measurements on intestinal aspiration biopsy specimens. Gut 37 (1995), 777–782.
107. 107 Shan, L., Molberg, O., Parrot, I., et al. Structural basis for gluten intolerance in celiac sprue. Science 297 (2002), 2275–2279.
108. 108 Menard, S., Cerf-Bensussan, N., Heyman, M., Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 3 (2010), 247–259.
109. 109 Lebreton, C., Menard, S., Abed, J., et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 143 (2012), 698–707 e1–4.
110. 110 Menard, S., Lebreton, C., Schumann, M., et al. Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol 180 (2012), 608–615.
111. 111 Zimmer, K.P., Fischer, I., Mothes, T., et al. Endocytotic segregation of gliadin peptide 31-49 in enterocytes. Gut 59 (2010), 300–310.
112. 112 Gassama-Diagne, A., Yu, W., ter Beest, M., et al. Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells. Nat Cell Biol 8 (2006), 963–970.
113. 113 Kierbel, A., Gassama-Diagne, A., Rocha, C., et al. Pseudomonas aeruginosa exploits a PIP3-dependent pathway to transform apical into basolateral membrane. J Cell Biol 177 (2007), 21–27.
114. 114 Rubio-Tapia, A., Murray, J.A., The liver in celiac disease. Hepatology 46 (2007), 1650–1658.
115. 115 Novacek, G., Miehsler, W., Wrba, F., et al. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gastroenterol Hepatol 11 (1999), 283–288.
116. 116 Luther, J., Garber, J.J., Khalili, H., et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol 1 (2015), 222–232.
117. 117 Wiest, R., Lawson, M., Geuking, M., Pathological bacterial translocation in liver cirrhosis. J Hepatol 60 (2014), 197–209.
118. 118 Gopalakrishnan, S., Tripathi, A., Tamiz, A.P., et al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 35 (2012), 95–101.
119. 119 Paterson, B.M., Lammers, K.M., Arrieta, M.C., et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 26 (2007), 757–766.
120. 120 Kelly, C.P., Green, P.H., Murray, J.A., et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 37 (2013), 252–262.
121. 121 Leffler, D.A., Kelly, C.P., Abdallah, H.Z., et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 107 (2012), 1554–1562.
122. 122 Leffler, D.A., Kelly, C.P., Green, P.H., et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 148 (2015), 1311–1319.